Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830.

@article{Carroll1985ImprovedGC,
  title={Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830.},
  author={Melissa J Carroll and Carolyn A Lister and Matthew V. Sennitt and N Stewart-Long and Michael Anthony Cawthorne},
  journal={Diabetes},
  year={1985},
  volume={34 11},
  pages={1198-204}
}
BRL 26830, (R*,R*)-(+/-)-methyl-4-(2-[(2-hydroxy-2-phenylethyl)amino]propyl)-benzoa te, is a new type of beta-adrenoceptor receptor agonist that combines antihyperglycemic and thermogenic properties. In C57Bl/KsJ db/db mice, treatment with BRL 26830 (50 mg of the hemifumarate salt/kg diet) decreased blood glucose concentration and normalized water intake. As judged by the normalization of polydipsia, BRL 26830 was effective within 2 days and the effect was maintained throughout a treatment… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.